v3.20.1
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenue
Expenses:    
Research and development 5,934 3,340
General and administrative 5,900 2,260
Operating expenses 11,834 5,600
Other income (expense):    
Interest income 323 92
Foreign exchange gains/( losses) (15) 2
Total other income 308 94
Net loss (11,526) (5,506)
Other comprehensive loss:    
Unrealized gain/(loss) on securities available-for-sale 9
Total comprehensive loss $ (11,526) $ (5,497)
Basic and diluted loss per common share (in dollars per share) $ (0.15) $ (0.14)
Weighted average number of common shares outstanding used in the calculation of (in thousands) Basic and diluted loss per common share (in shares) 76,227 39,846

Source